It's standing-room-only in Dallas for the inaugural Myeloma Day! We are experiencing a groundbreaking era in Myeloma research, and the conversations happening here today offer new hope and improved prospects for those affected by this challenging disease. #myelomaday #gduhem #greatdebatesandupdates #myeloma
Great Debates & Updates
Hospitals and Health Care
Malvern, PA 296 followers
Where Debate & Discussion Translate to Better Treatment
About us
Experience an educational event unlike any other. These unique, debate-style conferences, covering even more therapeutic areas in oncology than ever before, provide a comprehensive learning experience covering the latest scientific updates and controversial issues emerging in their field, mixed with audience interaction and insight on how this impacts their current practice. We’ve got you covered: in person, online, all-year long.
- Website
-
https://greatdebatesandupdates.com/
External link for Great Debates & Updates
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- Malvern, PA
- Specialties
- hematologic malignancies, gastrointestinal malignancies, women's oncology, and lung cancers
Updates
-
Myeloma Day starts at 8:45 AM this morning. Stop by the JW Marriott Dallas Arts District to pick up your complimentary registration badge. #myelomaday #greatdebatesandupdates #GDUHEM #myeloma #bloodcancer
-
There is still time to spend your Saturday with us. You can register in advance or on site at the JW Marriott Dallas Arts District. We hope to see you tomorrow: https://lnkd.in/eXP9inzv #myelomaday #greatdebatesandupdates #GDUHEM #hematologicmalignancies #myeloma #bloodcancer
-
Great Debates & Updates reposted this
At Great Debates & Updates in Women's Oncology, Bradley J. Monk, MD, Florida Cancer Specialists & Research Institute, discussed whether PARP inhibitors are the optimal maintenance therapy for patients with advanced epithelial ovarian cancer.
-
Can we count you in for Myeloma Day coming up this Saturday, May 11, at the JW Marriott Dallas Arts District? There is still time to register: https://lnkd.in/efCHyiHr #myelomaday #myeloma #greatdebatesandupdates #hematologicmalignancies #bloodcancer
Enhance your myeloma treatment approaches with this special one-day seminar! Join Joseph Mikhael in Dallas on May 11 to gain insights into the current landscape and recent updates - including the recent FDA Cilta-Cel approval. From diagnosis to treatment, we've got you covered with all the informative updates you need in this quickly evolving space. Register Now: https://lnkd.in/efCHyiHr #myelomaday #GDUHEM #greatdebatesandupdats
This content isn’t available here
Access this content and more in the LinkedIn app
-
Great Debates & Updates reposted this
Stage 4 Colon Cancer Survivor, Advocate, Blogger, NYC C5 Steering Committee, Certified Patient Navigator, Public Speaker, Consultant.
GI Cancers Alliance (https://lnkd.in/e4v8SDvK) is proud to announce our partnership w 'Great Debates & Updates in Gastrointestinal Malignancies' Elevate your perspective at #GDUGI & engage in thought-provoking conversations that spark change. Martha Raymond Hans Rueffert https://lnkd.in/ef_JuV-g
-
Great Debates & Updates reposted this
GI Cancers Alliance is proud to announce our partnership with 'Great Debates & Updates in Gastrointestinal Malignancies' Elevate your perspective at #GDUGI & engage in thought-provoking conversations that spark change. Register: https://lnkd.in/gWb_eJNJ
-
Great Debates & Updates reposted this
We are 10 days away from Great Debates & Updates in GI Malignancies! Are you going to be there? There's still time to register!
-
Thank you for your support at #GDUWO, Dr. Paolo Tarantino & Dr. Claudine Isaacs!
HER2-low: should we even test? Greatly enjoyed this debate with Claudine Isaacs in New York on the evolving paradigm of HER2 testing. My arguments: - YES, we should test, because low ≠ 0, as shown by DAISY and our real-world data with T-DXd - YES, we should test, since other options are available (or soon will be) for patients with HER2-0 disease (SG, Dato-DXd and beyond) - YES we should test, but… keep working at refining our testing. Digital pathology, quantitative proteomics and other innovative assays may soon replace IHC in the HER2-low space. Stay tuned.